PMID- 28845713
OWN - NLM
STAT- MEDLINE
DCOM- 20180108
LR  - 20181202
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 18
IP  - 15
DP  - 2017 Oct
TI  - Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a 
      systematic review.
PG  - 1543-1551
LID - 10.1080/14656566.2017.1373091 [doi]
AB  - OBJECTIVE: We conducted a systematic review to assess the efficacy and safety of 
      Thrombopoietin-receptor agonists (TPOras) for pediatric immune thrombocytopenia 
      (ITP). METHODS: We searched PubMed, Embase and Cochrane Library from their 
      earliest records to January 2017. Randomized controlled trials (RCTs) were 
      included. Primary outcomes were durable response and clinically significant 
      bleeding. Secondary outcomes were overall response, overall bleeding events, the 
      use of rescue medication and adverse events (AEs). RESULTS: Five randomized RCTs 
      (261participants) were included. Compared with placebo group, the proportion of 
      patients achieving durable platelet response was significantly higher in 
      Eltrombopag (P = 0.0004) or Romiplostim (P = 0.002) group, so was the overall 
      response in Eltrombopag [RR = 2.64, 95% CI (1.58, 4.44)] or Romiplostim [RR = 
      5.05, 95% CI (2.21, 11.53)] group. Both clinically significant bleeding (P = 
      0.04) and total bleeding (P = 0.01) in Eltrombopag group were significantly less 
      frequent than those in placebo group, while no significant difference between 
      Romiplostim and placebo group. The proportion of patients receiving rescue 
      medication, the incidence of overall AEs and serious AEs between TPO-receptor 
      agonists and placebo group were not significantly different. CONCLUSION: TPOras 
      might improve both durable and overall platelet response in pediatric ITP, 
      compared with placebo.
FAU - Zhang, Jiaxing
AU  - Zhang J
AUID- ORCID: 0000-0002-0178-7007
AD  - a Chinese Evidence-based Medicine Center , Sichuan University , Chengdu , China.
AD  - b Department of Pharmacy , Guizhou Provincial People's Hospital , Guiyang , 
      China.
FAU - Liang, Yi
AU  - Liang Y
AD  - c Health Outcomes and Pharmacy Practice, College of Pharmacy , The University of 
      Texas at Austin , TX , USA.
FAU - Ai, Yuan
AU  - Ai Y
AD  - d Department of Pediatric Hematology and Oncology , West China Second University 
      Hospital, Sichuan University , Chengdu , China.
FAU - Xie, Juan
AU  - Xie J
AD  - b Department of Pharmacy , Guizhou Provincial People's Hospital , Guiyang , 
      China.
FAU - Li, Youping
AU  - Li Y
AD  - a Chinese Evidence-based Medicine Center , Sichuan University , Chengdu , China.
FAU - Zheng, Wenyi
AU  - Zheng W
AD  - e Department of Laboratory Medicine , Karolinska Institute, Experimental Cancer 
      Medicine, Clinical Research Center , Stockholm , Sweden.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20170904
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Benzoates)
RN  - 0 (Hydrazines)
RN  - 0 (Pyrazoles)
RN  - 0 (Receptors, Fc)
RN  - 0 (Receptors, Thrombopoietin)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 9014-42-0 (Thrombopoietin)
RN  - GN5XU2DXKV (romiplostim)
RN  - S56D65XJ9G (eltrombopag)
SB  - IM
MH  - Benzoates/adverse effects/*therapeutic use
MH  - Child
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Hydrazines/adverse effects/*therapeutic use
MH  - Incidence
MH  - Platelet Count
MH  - Purpura, Thrombocytopenic, Idiopathic/blood/*drug therapy
MH  - Pyrazoles/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Receptors, Fc/*therapeutic use
MH  - Receptors, Thrombopoietin/*agonists
MH  - Recombinant Fusion Proteins/adverse effects/*therapeutic use
MH  - Thrombopoietin/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - Pediatric immune thrombocytopenia
OT  - eltrombopag
OT  - romiplostim
OT  - systematic review
OT  - thrombopoietin-receptor agonists
EDAT- 2017/08/29 06:00
MHDA- 2018/01/09 06:00
CRDT- 2017/08/29 06:00
PHST- 2017/08/29 06:00 [pubmed]
PHST- 2018/01/09 06:00 [medline]
PHST- 2017/08/29 06:00 [entrez]
AID - 10.1080/14656566.2017.1373091 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2017 Oct;18(15):1543-1551. doi: 
      10.1080/14656566.2017.1373091. Epub 2017 Sep 4.